UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of Bt plants on the development and survival of the parasitoid Cotesia plutellae (Hymenoptera: Braconidae) in susceptible and Bt-resistant larvae of the diamondback moth, Plutella xylostella (Lepidoptera: Plutellidae)

Journal of insect physiology, 2004-05, Vol.50 (5), p.435-443

2004

Volltextzugriff (PDF)

Insect-resistant transgenic plants

Trends in biotechnology (Regular ed.), 1998-04, Vol.16 (4), p.168-175

1998

Volltextzugriff (PDF)

Parasitoid behaviour and Bt plants

Nature (London), 1999-08, Vol.400 (6747), p.825-829

1999

Volltextzugriff (PDF)

Potential side effects of insect-resistant transgenic plants on arthropod natural enemies

Trends in biotechnology (Regular ed.), 1999-05, Vol.17 (5), p.210-216

1999

Volltextzugriff (PDF)

Host-plant mediated effects of transgenic maize on the insect parasitoid Campoletis sonorensis (Hymenoptera: Ichneumonidae)

Biological control, 2007-03, Vol.40 (3), p.362-369

2007

Volltextzugriff (PDF)

Tritrophic choice experiments with Bt plants, the diamondback moth (Plutella xylostella) and the parasitoid Cotesia plutellae

Transgenic research, 2003-06, Vol.12 (3), p.351-361

2003

Volltextzugriff (PDF)

Inheritance of resistance to Bt canola in a field-derived population of Plutella xylostella

Pest management science, 2003-11, Vol.59 (11), p.1197-1202

2003

Volltextzugriff (PDF)

Toxicological, Electrophysiological, and Molecular Characterisation of Knockdown Resistance to Pyrethroid Insecticides in the Diamondback Moth,Plutella xylostella(L.)

Pesticide biochemistry and physiology, 1998-05, Vol.59 (3), p.169-182

1998

Volltextzugriff (PDF)

Resistant cabbage cultivars change the susceptibility of Plutella xylostella to Bacillus thuringiensis

Agricultural and forest entomology, 2000-02, Vol.2 (1), p.33-38

2000

Volltextzugriff (PDF)

Laboratory studies on the effect of 'stress' on the susceptibility of the diamond moth (plutella xylostella) and the rose-grain aphid (metapolophium dirhodum) to insect pathogens

Schuler, Tanja H

1995

Volltextzugriff (PDF)

Gut Microbiota Promote Angiotensin II–Induced Arterial Hypertension and Vascular Dysfunction

Journal of the American Heart Association, 2016-09, Vol.5 (9), p.n/a

2016

Volltextzugriff (PDF)

Nox2+ myeloid cells drive vascular inflammation and endothelial dysfunction in heart failure after myocardial infarction via angiotensin II receptor type 1

Cardiovascular research, 2021-01, Vol.117 (1), p.162-177

2021

Volltextzugriff (PDF)

Insights into social insects from the genome of the honeybee Apis mellifera [Erratum: 2006 Nov. 23, v. 444, no. 7118, p. 512.]

Nature, 2006-10, Vol.443 (7114), p.931-949

2006

Volltextzugriff (PDF)

Initial results from the phase 2A trial of visugromab (CTL-002) + nivolumab in advanced/metastatic anti-PD1/-L1 relapsed/refractory solid tumors (The GDFATHER-TRIAL)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2501-2501

2023

Volltextzugriff (PDF)

A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS2658-TPS2658

2021

Volltextzugriff (PDF)

RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer: Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3566-3566

2021

Volltextzugriff (PDF)

PD-0413: The role of different chemotherapy protocols for concurrent CRT in locally advanced NSCLC

Radiotherapy and oncology, 2020-11, Vol.152, p.S223-S224

2020

Volltextzugriff (PDF)

Abstract P1-19-31: RIBECCA - A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole: Results of the third interim analysis

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P1-P1-19-31

2020

Volltextzugriff (PDF)

RIBECCA: A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole—Results of the first interim analysis

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.1051-1051

2018

Volltextzugriff (PDF)

RIBECCA: A phase IIIb, multicenter, open label study for women with estrogen receptor-positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole—Results of the second interim analysis

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.1061-1061

2019

Volltextzugriff (PDF)

A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS3617-TPS3617

2019

Volltextzugriff (PDF)

Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC): Primary endpoint and subgroup analysis of the CEBIFOX trial

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3568-3568

2015

Volltextzugriff (PDF)

Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC): An interim analysis of the CEBIFOX trial

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e14502-e14502

2013

Volltextzugriff (PDF)

Molecular dissection of effector mechanisms of RAS -induced resistance to monoclonal anti-EGFR antibodies

Journal of clinical oncology, 2012-02, Vol.30 (4_suppl), p.501-501

2012

Volltextzugriff (PDF)

Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.4080-4080

2013

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(26)

Publikationsform

Sprache

Englisch
(27)
Deutsch
(1)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Effects of Bt plants on the development and survival of the parasitoid Cotesia plutellae (Hymenoptera: Braconidae) in susceptible and Bt-resistant larvae of the diamondback moth, Plutella xylostella (Lepidoptera: Plutellidae)

Insect-resistant transgenic plants

Parasitoid behaviour and Bt plants

Potential side effects of insect-resistant transgenic plants on arthropod natural enemies

Host-plant mediated effects of transgenic maize on the insect parasitoid Campoletis sonorensis (Hymenoptera: Ichneumonidae)

Tritrophic choice experiments with Bt plants, the diamondback moth (Plutella xylostella) and the parasitoid Cotesia plutellae

Inheritance of resistance to Bt canola in a field-derived population of Plutella xylostella

Toxicological, Electrophysiological, and Molecular Characterisation of Knockdown Resistance to Pyrethroid Insecticides in the Diamondback Moth,Plutella xylostella(L.)

Resistant cabbage cultivars change the susceptibility of Plutella xylostella to Bacillus thuringiensis

Laboratory studies on the effect of 'stress' on the susceptibility of the diamond moth (plutella xylostella) and the rose-grain aphid (metapolophium dirhodum) to insect pathogens

Gut Microbiota Promote Angiotensin II–Induced Arterial Hypertension and Vascular Dysfunction

Nox2+ myeloid cells drive vascular inflammation and endothelial dysfunction in heart failure after myocardial infarction via angiotensin II receptor type 1

Insights into social insects from the genome of the honeybee Apis mellifera [Erratum: 2006 Nov. 23, v. 444, no. 7118, p. 512.]

Initial results from the phase 2A trial of visugromab (CTL-002) + nivolumab in advanced/metastatic anti-PD1/-L1 relapsed/refractory solid tumors (The GDFATHER-TRIAL)

A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER)

RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer: Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316)

PD-0413: The role of different chemotherapy protocols for concurrent CRT in locally advanced NSCLC

Abstract P1-19-31: RIBECCA - A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole: Results of the third interim analysis

RIBECCA: A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole—Results of the first interim analysis

RIBECCA: A phase IIIb, multicenter, open label study for women with estrogen receptor-positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole—Results of the second interim analysis

A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316)

Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC): Primary endpoint and subgroup analysis of the CEBIFOX trial

Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC): An interim analysis of the CEBIFOX trial

Molecular dissection of effector mechanisms of RAS -induced resistance to monoclonal anti-EGFR antibodies

Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas

Suchergebnisse filtern